Long-term follow-up of tacrolimus rescue therapy for renal allograft rejection by Naraghi, RM et al.
d!# 
all I ,\ 
Long-Term Follow-Up of Tacrolimus Rescue Therapy for Renal 
Allograft Rejection 
R.M. Naraghi, D. Smith, R. Shapiro, CA Vivas, HA Gritsch, V.P. Scantlebury, J. McCauley, 
P. Randhawa, A.J. Demetris, J. McMichael, J.J. Fung, T.E. Starzl, and M.L. Jordan 
THE EFFICACY of tacrolimus in primary renal trans-plantation! led us to evaluate this agent for rescue of 
resistant allograft rejection in 77 patients under primary 
cyclosporine (CyA)-based immunosuppression, in whom we 
reported a 74% salvage rate with a l3.9-month followup.2 
To evaluate the longevity of the observed effects of tacroli-
mus rescue, we herein present a report and the long-term 
follow-up of this group of patients. Between July 14, 1989 
and April 16. 1993. 77 patients (44 male, 33 female) with a 
mean age of 33.3 ± 12.4 years (range 2 to 59 years) failing 
CyA-based immunosuppression were converted to tacroli-
mus. Fifty-nine patients (77%) were primary transplant 
recipients and 18 (23%) had been retransplanted. Fifty-two 
patients (68%) were recipients of cadaveric grafts and 25 
(32%) live donor grafts. All patients considered for tacroli-
mus conversion had uncontrolled biopsy-proven rejection. 
Previous antirejection therapy had been administered to all 
77 patients in the form of bolus high-dose corticosteroids 
and 61 (79%) had also received at least one course of an 
antilymphocyte preparation. Tacrolimus was given at a 
standard daily dose of 0.3 mglkgld in divided doses every 12 
hours starting 12 hours after the last CvA dose. Statistical 
significance was calculated by Studenfs'{ test or chi-square 
analysis as appropriate. Successful tacrolimus conversion 
was defined as a return to baseline serum creatinine (sCr), 
and/or improvement on postconversion renal allograft bi-
opsy, and/or freedom from dialysis if the patient wa; dialysis 
dependent at the time of conversion. In our initial report on 
these 77 patients. we reported successful allograft salvage 
with tacrolimus conversion in 57 of 77 patients (74%) with 
a follow-up of 13.9 ± 9.1 months (range 2 to 34 months).2 
Of the 57 patients whose grafts were successfully rescued 
initially. 41'1 (84%) continue to have functioning grafts with 
a mean sCr of 2.1 ± 0.85 mgldL at a mean follow-up of 
41. 9 ± 12.1 months (range 16 to 62 months). There have 
heen nine late graft losses due to patient death (n = 3; two 
patients with functioning grafts and I with unknown allo-
graft function). chronic rejection (n = 5). and patient 
noncompliance (n = I). Of the 18 patients on dialysis at the 
time of conversion. 9 (50ey). continue to have functioning 
grafts with a mean sCr of 2.1 mgldL (mean follOW-lip 45.1 ;: 
11.9 months). In 61 patients who had received antilympho-
cytc preparations .. .19 (04r:r) continue to have functioning 
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grafts (mean ser 2.15 ± 0.9 mg/dL). In all 48 patients 
rescued, prednisone doses have been lowered from 22.2 ± 
7.2 mg/d preconversion to 4.6 ± 4.0 mg/d postconversion, 
and 18 (38%) patients are not currently on steroids. 
Since its introduction in the early 1980s, CyA has become 
the mainstay of contemporary posttransplant immunosup-
pression. Unfortunately, even with triple and quadruple-
drug CyA immunosuppression, a significant number of 
allografts are lost to resistant rejection.3 Tacrolimus is an 
immunosuppressant that has been used with encouraging 
results in renal transplantation. The utility of tacrolimus as 
a potential rescue agent was initially shown in 57 of 77 
(74%) patients with a follow-up of 14 months, including 9 of 
18 patients (50%) who were on dialysis at the time of 
conversion, 4 of 10 (40% ) whose graft had never functioned 
from the time of transplantation, and 48 of 61 (79%) who 
had received at least one course of an antilymphocyte 
preparation prior to rescue. Further decreases in steroid 
doses were achieved in 56 (98%) and prednisone was 
stopped completely in 12 (21 o/c). At a mean follow-up of 
41.9 ± 12.1 months (range 16 to 62 months), 48 (84%) of 
the 57 patients whose grafts were successfully rescued 
continue to have functioning grafts with a mean sCr of 
2.1 ± 0.85 mg/d L. Hence, long-term success with tacroli-
mus rescue is observed with a low (11 %) incidence of late 
graft loss. which appears to be primarily due to chronic 
rejection. Tacrolimus is therefore an effcctive long-term 
rescue agent and should he part ofthc transplant clinician's 
armamentarium for resistant renal allograft rejcction. 
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